Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company targeting the domestic pharmaceutical manufacturing and broader healthcare sector, with an emphasis on businesses aligned with reshoring drug production and life-sciences supply chains within the United States. The company filed an amended S-1 registration statement with the SEC on November 25, 2024, under accession number 0001213900-24-102238, reflecting active progress toward completing its initial public offering in the 2024–2025 timeframe. The sponsor has not been publicly disclosed in available filings to date. Sign up at SpacDesk for DMAAR's full sponsor profile, deal terms, and comparable SPAC transaction data.